Newsroom

Sorted by: Latest

-

First Trust Global Funds PLC UK Regulatory Announcement: Net Asset Value(s)

LONDON--(BUSINESS WIRE)--  Funds Date TIDM ISIN Code Shares in Issue Currency Net Asset Value NAV/per Share First Trust Low Duration Global Government Bond UCITS ETF 08.01.2026 FGOV LN IE00BKS2X200   33,638.00 GBP    498,781.05   17.084  ...
-

Kezar Life Sciences Announces Regulatory Update on Zetomipzomib Program in Autoimmune Hepatitis

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Kezar Life Sciences, Inc. (Nasdaq:KZR), a clinical-stage biotechnology company developing novel small molecule therapeutics to treat unmet needs in immune-mediated diseases, today announced that the Food and Drug Administration (FDA) Division of Hepatology and Nutrition has granted Kezar a Type C meeting for the first quarter to discuss the development of zetomipzomib, a novel, selective inhibitor of the immunoproteasome, in patients with autoimmune...
-

Aurora Therapeutics Launches to Realize Potential of Personalized Gene Editing for Millions of Patients with Rare Diseases

BOSTON--(BUSINESS WIRE)--Aurora Therapeutics today announced its official launch to transform personalized gene editing from a one-patient breakthrough into a scalable model capable of bringing therapies to millions of patients with rare diseases. The company launches with a $16 million seed financing from Menlo Ventures to create the first platform for treating rare genetic mutations that have historically been impossible to address at scale. Aurora was founded by Jennifer Doudna, Ph.D., CRISP...
-

Kinaxis nomeia Razat Gaurav como o novo CEO

OTTAWA, Ontário--(BUSINESS WIRE)--A Kinaxis® Inc. (TSX:KXS), líder global em orquestração de cadeia de suprimentos, anunciou hoje a nomeação de Razat Gaurav como CEO, em vigor a partir de 12 de janeiro de 2026, a data oficial do seu início, quando ele também começará a ser parte integrante da Diretoria da Kinaxis. "Após uma busca rigorosa, a Diretoria selecionou Razat para liderar a empresa como CEO", afirmou Bob Courteau, CEO interino e presidente da Diretoria da Kinaxis. "Os vinte e cinco ano...
-

Oklo, Meta Announce Agreement in Support of 1.2 GW Nuclear Energy Development in Southern Ohio

PIKE COUNTY, Ohio--(BUSINESS WIRE)--Oklo Inc. (NYSE: OKLO) (Oklo), an advanced nuclear technology company, announced an agreement with Meta Platforms, Inc. (Nasdaq: META) that advances Oklo’s plans to develop a 1.2 GW power campus in Pike County, Ohio, to support Meta’s data centers in the region. The agreement provides a mechanism for Meta to prepay for power and provide funding to advance project certainty for Oklo’s Aurora powerhouse deployment. Oklo will use the funds to secure nuclear fuel...
-

Pacifico Energy Achieves Commercial Operations at Sunpro Wind Farm in Vietnam’s Mekong Delta

VĨNH LONG, Vietnam--(BUSINESS WIRE)--Pacifico Energy Vietnam (“PEV”), the Vietnam-based development platform of Pacifico Energy Group (“PEG”), a leading global energy infrastructure developer, today announced the commencement of commercial operations at its 30 MW Sunpro Wind Farm (“Sunpro”), adding new power capacity to Vietnam’s national grid, supporting the country’s transition to clean energy. Located in Thới Thuận Commune, Vĩnh Long Province in the Mekong Delta, Sunpro achieved commercial o...
-

Insulet to Announce Fourth Quarter and Full Year 2025 Financial Results on February 18, 2026 

ACTON, Mass.--(BUSINESS WIRE)--Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced it will report financial results for the fourth quarter and full year of 2025 on February 18, 2026, before the opening of the financial markets. In connection with the release, management will host a conference call that day at 8:00 a.m. (Eastern Time). The link to the live call will be available on...
-

Qube Research & Technologies LTD UK Regulatory Announcement: Form 8.3

LONDON--(BUSINESS WIRE)--  FORM 8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORE Rule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION (a) Full name of discloser: Qube Research & Technologies Limited (b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiari...
-

ARDT INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Ardent Health, Inc. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit

SAN DIEGO--(BUSINESS WIRE)--The case alleges Ardent Health misled investors by overstating accounts receivable and concealing insufficient medical malpractice insurance....
-

Linde Announces Fourth Quarter 2025 Earnings and Conference Call Schedule

WOKING, England--(BUSINESS WIRE)--Linde (Nasdaq: LIN) will release its fourth quarter 2025 financial results by 06:00 EST/midday CET on Thursday, February 5, 2026. The Company will host and webcast its conference call at 09:00 EST/15:00 CET, which will be available to the public and the media in listen-only mode. Live conference call US Toll-Free Dial-In Number: 1 888 770 7292 UK Toll-Free Dial-In Number: 0800 358 0970 Access code: 6877110   Live webcast (listen-only)   https://www.linde.com/in...